In conversation with... Peter De Cruz

from Listen to The Lancet Gastroenterology & Hepatology · host The Lancet

Peter De Cruz (University of Melbourne) discusses the PREDICT-UC trial of intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.

Episode metadata supplied by the publisher feed · Published Nov 6, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

In conversation with... Peter De Cruz

0:00 14:42

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Gastroenterology & Hepatology?

This episode is 14 minutes long.

When was this Listen to The Lancet Gastroenterology & Hepatology episode published?

This episode was published on November 6, 2024.

Can I download this Listen to The Lancet Gastroenterology & Hepatology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!